Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Viagra
VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3–4
HOS-088776 · Präparat HOS-083727
3
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 514cc64ce37e263f485f6b2f45b7111a3d36cb54fd009b79d8c7cd281fe5cd15 · Zeichen 469–682 im Abschnitt
Gegenanzeigen · Viagra
VIAGRA 50 mg orodispersible tablets · Abschnitt 4.3 · PDF-Seite 17
HOS-088836 · Präparat HOS-083727
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 8f544c13b61bef2b6bc6eeae57ce7b53ff1b75095b32b53e2a06ade095001471 · Zeichen 413–623 im Abschnitt
Gegenanzeigen · Viagra
VIAGRA 50 mg orodispersible films · Abschnitt 4.3 · PDF-Seite 31
HOS-088887 · Präparat HOS-083727
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage abbea2eded8461c7f0476e1851671e3ba4ac296dfea68a7ea0ff323410b31eaf · Zeichen 413–623 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088799 · Präparat HOS-083727
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 711bfff2b0d0c3eb5f18a8052209d238d91d9092bec736b81080210041fff983 · Zeichen 5500–6512 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 50 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 20–21
HOS-088855 · Präparat HOS-083727
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5
inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including
sildenafil, is contraindicated (see section 4.3).
20
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage b828f8947fcc03e3016c59c4b438ec2d0048266fb83b7e546a68a4e887ecc849 · Zeichen 5054–6570 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 50 mg orodispersible films · Abschnitt 4.5 · PDF-Seite 34–35
HOS-088906 · Präparat HOS-083727
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
34
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In
these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg,
9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
light-headedness, but not syncope.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage 932582cb7cc2322730690119de4f4ff689c91448f308fb14d34667683466a2a1 · Zeichen 5501–6569 im Abschnitt
Gegenanzeigen · Revatio
Revatio 20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-114920 · Präparat HOS-094193
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Combination with the most potent of the CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir)
(see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592) ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 459ad0687f3737f4f970b1b61385ed61356a294143302bfb2cadf8e89c4466b6 · Zeichen 246–577 im Abschnitt
Gegenanzeigen · Revatio
Revatio 0.8 mg/ml solution for injection · Abschnitt 4.3 · PDF-Seite 23
HOS-114980 · Präparat HOS-094193
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 8f544c13b61bef2b6bc6eeae57ce7b53ff1b75095b32b53e2a06ade095001471 · Zeichen 246–456 im Abschnitt
Gegenanzeigen · Revatio
Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.3 · PDF-Seite 41–42
HOS-115040 · Präparat HOS-094193
41
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 177e7758111a4d0eb1cfc5fc32bb8f50fd7e95d7332f5fff618e734bf60a4cac · Zeichen 300–514 im Abschnitt
Wechselwirkungen · Revatio
Revatio 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-114953 · Präparat HOS-094193
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and
sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign
prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean
additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and
8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking
alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 14be1b2f7f9bdf4d88008c516b2997ace4c575593a1757a4a2098a060188e12d · Zeichen 8515–9479 im Abschnitt
Wechselwirkungen · Revatio
Revatio 0.8 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 28
HOS-115016 · Präparat HOS-094193
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and oral
sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign
prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean
additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and
8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking
alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 9f60aa292145c8703655e91205ca94757dadf404d84725263fb6011b7fada63a · Zeichen 9348–10317 im Abschnitt
Wechselwirkungen · Revatio
Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 46
HOS-115074 · Präparat HOS-094193
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and
sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign
prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean
additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and
8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg,
11/4 mmHg, and 4/5 mmHg, respectively were observed. When sildenafil and doxazosin were
administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports
of patients who experienced symptomatic postural hypotension. These reports included dizziness and
lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking
alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxazosin (HOS-088800) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 14be1b2f7f9bdf4d88008c516b2997ace4c575593a1757a4a2098a060188e12d · Zeichen 8518–9482 im Abschnitt
Gegenanzeigen · Sildenafil ratiopharm
Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil ratiopharm 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-121653 · Präparat HOS-095413
The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-06-24T11:00:00Z · SHA-256 c808d2606faf49a55ff479538c23c7b32973eab6a82cf87d69b7ee7085cb369e · Passage 8f544c13b61bef2b6bc6eeae57ce7b53ff1b75095b32b53e2a06ade095001471 · Zeichen 413–623 im Abschnitt
Wechselwirkungen · Sildenafil ratiopharm
Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil ratiopharm 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-121696 · Präparat HOS-095413
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to
symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours
post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drug interaction studies, the
alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) doxazosin (HOS-088800)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-06-24T11:00:00Z · SHA-256 c808d2606faf49a55ff479538c23c7b32973eab6a82cf87d69b7ee7085cb369e · Passage 105f7318ce54dafe8516e2f46fecd0361f98290214e18f89df22c65dbdf64c1e · Zeichen 5503–5901 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-131695 · Präparat HOS-097124
Ceritinib has been classified in vivo as a strong CYP3A4 inhibitor and has the potential to interact with
medicinal products that are metabolised by CYP3A, which may lead to increased serum
concentrations of the other product. Co-administration of a single dose of midazolam (a sensitive
CYP3A substrate) following 3 weeks of ceritinib dosing in patients (750 mg daily fasted) increased
the midazolam AUCinf (90% CI) by 5.4-fold (4.6, 6.3) compared to midazolam alone.
Co-administration of ceritinib with substrates primarily metabolised by CYP3A or CYP3A substrates
known to have narrow therapeutic indices (e.g. alfuzosin, amiodarone, cisapride, ciclosporin,
dihydroergotamine, ergotamine, fentanyl, pimozide, quetiapine, quinidine, lovastatin, simvastatin,
sildenafil, midazolam, triazolam, tacrolimus, alfentanil and sirolimus) should be avoided and
alternative medicinal products that are less sensitive to CYP3A4 inhibition should be used if possible.
If unavoidable, dose reduction for co-administered medicinal products that are CYP3A substrates with
narrow therapeutic indices should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) quinidine (HOS-085593) lovastatin (HOS-086157) simvastatin (HOS-086158) midazolam (HOS-086167) alfuzosin (HOS-086139) amiodarone (HOS-085596) cisapride (HOS-085610) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) fentanyl (HOS-086196) pimozide (HOS-085600) quetiapine (HOS-086150) sildenafil (HOS-086162) triazolam (HOS-086168) tacrolimus (HOS-085202) alfentanil (HOS-109375) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 8c077815baee1cc86d1631acdc9514aeea609ffa511fd705feb86861d6e3d369 · Zeichen 3957–5064 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 34
HOS-131749 · Präparat HOS-097124
Ceritinib has been classified in vivo as a strong CYP3A4 inhibitor and has the potential to interact with
medicinal products that are metabolised by CYP3A, which may lead to increased serum
concentrations of the other product. Co-administration of a single dose of midazolam (a sensitive
CYP3A substrate) following 3 weeks of ceritinib dosing in patients (750 mg daily fasted) increased
the midazolam AUCinf (90% CI) by 5.4-fold (4.6, 6.3) compared to midazolam alone.
Co-administration of ceritinib with substrates primarily metabolised by CYP3A or CYP3A substrates
known to have narrow therapeutic indices (e.g. alfuzosin, amiodarone, cisapride, ciclosporin,
dihydroergotamine, ergotamine, fentanyl, pimozide, quetiapine, quinidine, lovastatin, simvastatin,
sildenafil, midazolam, triazolam, tacrolimus, alfentanil and sirolimus) should be avoided and
alternative medicinal products that are less sensitive to CYP3A4 inhibition should be used if possible.
If unavoidable, dose reduction for co-administered medicinal products that are CYP3A substrates with
narrow therapeutic indices should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) amiodarone (HOS-085596) cisapride (HOS-085610) midazolam (HOS-086167) alfuzosin (HOS-086139) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) fentanyl (HOS-086196) pimozide (HOS-085600) quetiapine (HOS-086150) quinidine (HOS-085593) lovastatin (HOS-086157) simvastatin (HOS-086158) sildenafil (HOS-086162) triazolam (HOS-086168) tacrolimus (HOS-085202) alfentanil (HOS-109375) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 8c077815baee1cc86d1631acdc9514aeea609ffa511fd705feb86861d6e3d369 · Zeichen 3957–5064 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.